Lobe Sciences ends FY 2025 with cash of $5.85-million

Executive Summary

• Lobe Sciences Ltd. reported its audited financial results for the fiscal year ended August 31, 2025, highlighting a significantly strengthened balance sheet and improved liquidity position following a leadership transition and board renewal in late 2024.
• The company executed a strategic restructuring by transferring its lead asset, L-130, to its subsidiary Cynaptec Pharmaceuticals, which subsequently raised $8.46 million in financing at a $22.56 million post-money valuation to limit dilution at the parent level.
• Operational progress includes the completion of Phase 1a studies for L-130 and the refinement of the S-100 strategy for sickle cell disease, with the company aiming to advance core development programs through disciplined milestone execution in FY 2026.

Key Details

• Cash Position: Cash increased to $5,854,118 on August 31, 2025, compared to $237,772 on August 31, 2024.
• Working Capital: Improved to a surplus of $5,163,526, reversing a deficit of $2,008,849 in FY 2024.
• Debt and Liabilities:
  • The current portion of convertible notes was eliminated on August 31, 2025 (previously $641,374).
  • Derivative liability decreased to $205,105 from $603,724.
• Investments: Short-term investments of $1,686,688 were held on August 31, 2025 (none reported in FY 2024).
• Net Loss: Reported a net loss attributed to the parent company of $4,861,611 for FY 2025, compared to $4,420,727 in FY 2024.
• Loss Per Share: Three cents for FY 2025, compared to four cents for FY 2024.
• Strategic Financing: Completed a subsidiary-level financing for Cynaptec Pharmaceuticals that raised $8.46 million at a $22.56 million post-money valuation, with Lobe retaining a 64% ownership interest.
• Product Pipeline (Cynaptec/L-130):
  • L-130 is a novel, patented, oral, stable analog of psilocin for chronic cluster headache and substance use disorder.
  • Phase 1a study in healthy volunteers and supporting preclinical work have been completed internationally.
  • Development plan and partnership strategy are being advanced in line with FDA pre-IND correspondence guidance.
• Product Pipeline (Altemia/S-100):
  • S-100 is an early-stage therapeutic candidate for sickle cell disease based on a patented lipid-based formulation containing docosahexaenoic acid and eicosapentaenoic acid.
  • The company is maintaining limited preliminary commercialization activities for a proprietary medical food, focusing on assessing third-party reimbursement pathways.
• Market Context: Management noted that Lobe's market capitalization remained below $5.0 million during FY 2025, making parent-level financings highly dilutive, which drove the decision to structure development through subsidiaries.

Notable Quotes

• "Fiscal 2025 was about strengthening Lobe's balance sheet and funding our core assets responsibly. Advancing L-130 through Cynaptec Pharmaceuticals Inc. allowed us to secure development capital while limiting dilution at Lobe, which we believe better aligns capital with asset value." — Dr. Frederick D. Sancilio, Chairman and CEO